関節痛の注射市場：注射タイプ、関節タイプ、流通チャネル別-2025-2030年の世界予測

関節痛の注射市場は、2023年に45億5,000万米ドルと評価され、2024年には50億4,000万米ドルに達すると予測され、CAGR 10.94％で成長し、2030年には94億2,000万米ドルになると予測されています。

関節痛の注射は、関節炎やその他の退行性疾患など、関節に関連する様々な病気に苦しむ人々の不快感を和らげ、可動性を向上させることを目的とした重要なヘルスケア介入です。これらの注射は、副腎皮質ステロイド、ヒアルロン酸、その他の生物学的注射剤を含む幅広い製品を包含しています。その必要性は、内服薬や理学療法では不十分な場合、特に炎症と痛みに直接作用することで、的を絞った緩和を提供できることにあります。関節痛の注射の用途は、整形外科クリニック、病院、専門の疼痛管理センターなど多岐にわたり、主に高齢化社会とスポーツ関連傷害のある人々に対応しています。最終用途には、老人医療、リウマチ、スポーツ医学などが含まれます。

関節痛の注射市場は、慢性関節疾患の有病率の増加、製剤技術の進歩、低侵襲治療に対する需要の高まりなどの要因から大きな影響を受けています。再生細胞治療のような新規注射剤の開発や、先進医療へのアクセスが急増している新興経済諸国における市場開拓が潜在的な機会です。企業は、競争力を維持するために、イノベーションを促進し製品ポートフォリオを拡大するために、ヘルスケアプロバイダーや研究機関との提携に注力すべきです。しかし、同市場は、高度な注射療法に伴う高コストや、製品上市を遅らせる厳しい規制環境などの制約に直面しています。さらに、非侵襲的な代替療法に対する患者の嗜好が、市場成長の課題となっています。

有望な展望をもたらす革新的研究開発分野には、より長持ちする製剤の開発、遺伝子プロファイリングに基づく注射療法の個別化、治療結果を効果的にモニタリングするためのデジタルヘルスソリューションの統合などがあります。市場はダイナミックで、急速な技術進歩や新規参入を特徴とし、競争は激化するがイノベーションも促進されます。こうした機会を捉えるため、企業は研究開発への投資、戦略的パートナーシップの優先、規制基準への準拠の維持に努め、進化する状況を活用し、ヘルスケア分野の複雑な需要に応えていく必要があります。

市場力学：急速に進化する関節痛の注射市場の主要市場インサイトを公開

関節痛の注射市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 全世界における関節障害の有病率の増加
  • 関節リウマチ、変形性関節症、脊椎疾患、重度の四肢外傷の増加
  • 政府機関による啓発プログラムの提供
• 市場抑制要因
  • 関節痛の注射の高コスト
• 市場機会
  • 変形性関節症の疼痛治療の進歩
  • 関節内注射の利点に関する意識の高まり
• 市場の課題
  • 注射に関する認識不足

ポーターの5つの力：関節痛の注射市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：関節痛の注射市場における外部からの影響の把握

外部マクロ環境要因は、関節痛の注射市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析関節痛の注射市場における競合情勢の把握

関節痛の注射市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的な意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス関節痛の注射市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、関節痛の注射市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨関節痛の注射市場における成功への道筋を描く

関節痛の注射市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で関節疾患の罹患率が増加
    • 関節リウマチ、変形性関節症、脊椎疾患、重度の四肢外傷の症例が増加
    • 政府機関による啓発プログラムの利用可能性
  • 抑制要因
    • 関節痛の注射のコストが高い
  • 機会
    • 変形性関節症の痛み治療の進歩
    • 関節内注射の利点についての認識の高まり
  • 課題
    • 注射に関する認識の欠如
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 関節痛の注射市場注射の種類別

• コルチコステロイド注射
• ヒアルロン酸注射

第7章 関節痛の注射市場関節タイプ別

• 脊椎の椎間関節
• 股関節
• 膝と足首
• 肩と肘

第8章 関節痛の注射市場：流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局

第9章 南北アメリカの関節痛の注射市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の関節痛の注射市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの関節痛の注射市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Anika Therapeutics, Inc.
• Asterisk Laboratories（I）Pvt. Ltd.
• Bioventus LLC
• Chugai Pharmaceutical Co., Ltd.
• Ferring B.V.
• Henry Schein, Inc.
• Hetero Healthcare Limited
• Krosyl Pharmaceuticals Pvt. Ltd.
• Medilink Pharma
• Pfizer Inc.
• Salavidas Pharmaceutical Pvt. Ltd.
• Sanofi S.A.
• Seikagaku Corporation
• TEENA LABS LTD
• Wellona Pharma
• Zimmer Biomet Holdings, Inc.

LIST OF FIGURES

• FIGURE 1. JOINT PAIN INJECTIONS MARKET RESEARCH PROCESS
• FIGURE 2. JOINT PAIN INJECTIONS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INJECTION TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INJECTION TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES JOINT PAIN INJECTIONS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES JOINT PAIN INJECTIONS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. JOINT PAIN INJECTIONS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. JOINT PAIN INJECTIONS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. JOINT PAIN INJECTIONS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. JOINT PAIN INJECTIONS MARKET DYNAMICS
• TABLE 7. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INJECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROID INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY FACET JOINTS OF THE SPINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HIP JOINT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY KNEE & ANKLE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY SHOULDER & ELBOW, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY INJECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA JOINT PAIN INJECTIONS MARKET SIZE, BY INJECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL JOINT PAIN INJECTIONS MARKET SIZE, BY INJECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 29. CANADA JOINT PAIN INJECTIONS MARKET SIZE, BY INJECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 30. CANADA JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2030 (USD MILLION)
• TABLE 31. CANADA JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO JOINT PAIN INJECTIONS MARKET SIZE, BY INJECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES JOINT PAIN INJECTIONS MARKET SIZE, BY INJECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES JOINT PAIN INJECTIONS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET SIZE, BY INJECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA JOINT PAIN INJECTIONS MARKET SIZE, BY INJECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 46. CHINA JOINT PAIN INJECTIONS MARKET SIZE, BY INJECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 47. CHINA JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2030 (USD MILLION)
• TABLE 48. CHINA JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 49. INDIA JOINT PAIN INJECTIONS MARKET SIZE, BY INJECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 50. INDIA JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2030 (USD MILLION)
• TABLE 51. INDIA JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA JOINT PAIN INJECTIONS MARKET SIZE, BY INJECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN JOINT PAIN INJECTIONS MARKET SIZE, BY INJECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA JOINT PAIN INJECTIONS MARKET SIZE, BY INJECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES JOINT PAIN INJECTIONS MARKET SIZE, BY INJECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE JOINT PAIN INJECTIONS MARKET SIZE, BY INJECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA JOINT PAIN INJECTIONS MARKET SIZE, BY INJECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN JOINT PAIN INJECTIONS MARKET SIZE, BY INJECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND JOINT PAIN INJECTIONS MARKET SIZE, BY INJECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM JOINT PAIN INJECTIONS MARKET SIZE, BY INJECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY INJECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK JOINT PAIN INJECTIONS MARKET SIZE, BY INJECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT JOINT PAIN INJECTIONS MARKET SIZE, BY INJECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND JOINT PAIN INJECTIONS MARKET SIZE, BY INJECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE JOINT PAIN INJECTIONS MARKET SIZE, BY INJECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY JOINT PAIN INJECTIONS MARKET SIZE, BY INJECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL JOINT PAIN INJECTIONS MARKET SIZE, BY INJECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 101. ITALY JOINT PAIN INJECTIONS MARKET SIZE, BY INJECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 102. ITALY JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2030 (USD MILLION)
• TABLE 103. ITALY JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS JOINT PAIN INJECTIONS MARKET SIZE, BY INJECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA JOINT PAIN INJECTIONS MARKET SIZE, BY INJECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY JOINT PAIN INJECTIONS MARKET SIZE, BY INJECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 113. POLAND JOINT PAIN INJECTIONS MARKET SIZE, BY INJECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 114. POLAND JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2030 (USD MILLION)
• TABLE 115. POLAND JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 116. QATAR JOINT PAIN INJECTIONS MARKET SIZE, BY INJECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 117. QATAR JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2030 (USD MILLION)
• TABLE 118. QATAR JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA JOINT PAIN INJECTIONS MARKET SIZE, BY INJECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA JOINT PAIN INJECTIONS MARKET SIZE, BY INJECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY INJECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN JOINT PAIN INJECTIONS MARKET SIZE, BY INJECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN JOINT PAIN INJECTIONS MARKET SIZE, BY INJECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND JOINT PAIN INJECTIONS MARKET SIZE, BY INJECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY JOINT PAIN INJECTIONS MARKET SIZE, BY INJECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES JOINT PAIN INJECTIONS MARKET SIZE, BY INJECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM JOINT PAIN INJECTIONS MARKET SIZE, BY INJECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 146. JOINT PAIN INJECTIONS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 147. JOINT PAIN INJECTIONS MARKET, FPNV POSITIONING MATRIX, 2023

The Joint Pain Injections Market was valued at USD 4.55 billion in 2023, expected to reach USD 5.04 billion in 2024, and is projected to grow at a CAGR of 10.94%, to USD 9.42 billion by 2030.

Joint pain injections are a critical healthcare intervention aimed at alleviating discomfort and improving mobility for individuals suffering from various joint-related ailments, such as arthritis and other degenerative conditions. These injections encompass a broad range of products, including corticosteroids, hyaluronic acid, and other biological injectables. Their necessity arises from their ability to provide targeted relief in cases where oral medications or physical therapies may be insufficient, particularly in addressing inflammation and pain directly at the site. The application of joint pain injections spans orthopedic clinics, hospitals, and specialized pain management centers, catering mainly to an aging population and individuals with sports-related injuries. The end-use scope broadly includes geriatric care, rheumatology, and sports medicine.

The market for joint pain injections is significantly influenced by factors such as increasing prevalence of chronic joint conditions, advancements in formulation technologies, and a rising demand for minimally invasive treatments. Potential opportunities lie in the development of novel injectables, like regenerative cell therapies, and expanding geographic markets in emerging economies, where access to advanced medical treatments is burgeoning. Companies should focus on collaborations with healthcare providers and research institutions to foster innovation and expand their product portfolios to stay competitive. However, the market faces limitations such as high costs associated with advanced injectable therapies and stringent regulatory environments that can delay product launches. Additionally, patient preference for non-invasive alternatives presents a challenge to market growth.

Innovation and research areas that present promising prospects include the development of longer-lasting formulations, personalization of injectable therapies based on genetic profiling, and integration of digital health solutions to monitor treatment outcomes effectively. The market is dynamic, characterized by rapid technological advancements and the entry of new players, which intensifies competition but also drives innovation. To seize these opportunities, businesses should invest in R&D, prioritize strategic partnerships, and maintain compliance with regulatory standards to harness the evolving landscape and meet the intricate demands of the healthcare sector.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Joint Pain Injections Market

The Joint Pain Injections Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing prevalence of joint disorders across globe
  • Rising cases of rheumatoid arthritis, osteoarthritis, spinal disorders, and severe limb trauma
  • Availability of awareness programs by government organizations
• Market Restraints
  • High cost of the joint pain injections
• Market Opportunities
  • Advancement in osteoarthritis pain treatment
  • Growing awareness about benefits of intra-articular injections
• Market Challenges
  • Lack of awareness regarding injections

Porter's Five Forces: A Strategic Tool for Navigating the Joint Pain Injections Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Joint Pain Injections Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Joint Pain Injections Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Joint Pain Injections Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Joint Pain Injections Market

A detailed market share analysis in the Joint Pain Injections Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Joint Pain Injections Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Joint Pain Injections Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Joint Pain Injections Market

A strategic analysis of the Joint Pain Injections Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Joint Pain Injections Market, highlighting leading vendors and their innovative profiles. These include Anika Therapeutics, Inc., Asterisk Laboratories (I) Pvt. Ltd., Bioventus LLC, Chugai Pharmaceutical Co., Ltd., Ferring B.V., Henry Schein, Inc., Hetero Healthcare Limited, Krosyl Pharmaceuticals Pvt. Ltd., Medilink Pharma, Pfizer Inc., Salavidas Pharmaceutical Pvt. Ltd., Sanofi S.A., Seikagaku Corporation, TEENA LABS LTD, Wellona Pharma, and Zimmer Biomet Holdings, Inc..

Market Segmentation & Coverage

This research report categorizes the Joint Pain Injections Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Injection Type, market is studied across Corticosteroid Injections and Hyaluronic Acid Injections.
• Based on Joint Type, market is studied across Facet Joints of the Spine, Hip Joint, Knee & Ankle, and Shoulder & Elbow.
• Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing prevalence of joint disorders across globe
    • 5.1.1.2. Rising cases of rheumatoid arthritis, osteoarthritis, spinal disorders, and severe limb trauma
    • 5.1.1.3. Availability of awareness programs by government organizations
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of the joint pain injections
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancement in osteoarthritis pain treatment
    • 5.1.3.2. Growing awareness about benefits of intra-articular injections
  • 5.1.4. Challenges
    • 5.1.4.1. Lack of awareness regarding injections
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Joint Pain Injections Market, by Injection Type

• 6.1. Introduction
• 6.2. Corticosteroid Injections
• 6.3. Hyaluronic Acid Injections

7. Joint Pain Injections Market, by Joint Type

• 7.1. Introduction
• 7.2. Facet Joints of the Spine
• 7.3. Hip Joint
• 7.4. Knee & Ankle
• 7.5. Shoulder & Elbow

8. Joint Pain Injections Market, by Distribution Channel

• 8.1. Introduction
• 8.2. Hospital Pharmacies
• 8.3. Online Pharmacies
• 8.4. Retail Pharmacies

9. Americas Joint Pain Injections Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Joint Pain Injections Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Joint Pain Injections Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Anika Therapeutics, Inc.
• 2. Asterisk Laboratories (I) Pvt. Ltd.
• 3. Bioventus LLC
• 4. Chugai Pharmaceutical Co., Ltd.
• 5. Ferring B.V.
• 6. Henry Schein, Inc.
• 7. Hetero Healthcare Limited
• 8. Krosyl Pharmaceuticals Pvt. Ltd.
• 9. Medilink Pharma
• 10. Pfizer Inc.
• 11. Salavidas Pharmaceutical Pvt. Ltd.
• 12. Sanofi S.A.
• 13. Seikagaku Corporation
• 14. TEENA LABS LTD
• 15. Wellona Pharma
• 16. Zimmer Biomet Holdings, Inc.